Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 180 articles:
HTML format



Single Articles


    July 2021
  1. JOHNSON VALIENTE A, Liem KS, Schwarz KB, Rosenthal P, et al
    The Inflammatory Cytokine Profile Associated with Liver Damage is Broader and Stronger in Chronic Hepatitis B Patients Compared to Acute Hepatitis B Patients.
    J Infect Dis. 2021 Jul 21. pii: 6324833. doi: 10.1093.
    PubMed     Abstract available


  2. SPRADLING PR, Xing J, Harris AM, Ly KN, et al
    Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018.
    J Infect Dis. 2021 Jul 12. pii: 6319558. doi: 10.1093.
    PubMed     Abstract available


  3. GU S, Wang W, Ye G, Chen C, et al
    Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells.
    J Infect Dis. 2021 Jul 2. pii: 6313212. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  4. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  5. HSU YC, Yeh ML, Wong GL, Chen CH, et al
    Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    J Infect Dis. 2021 May 17. pii: 6276897. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  6. GONZALEZ HC, Trudeau S, Gordon SC
    Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.
    J Infect Dis. 2021 Apr 27. pii: 6254533. doi: 10.1093.
    PubMed    


  7. LY KN, Xing J, Spradling PR
    Trends in Prevalence and Characteristics of Resolved and Current Hepatitis B among US-Born Persons: National Health and Nutrition Examination Survey, 2001-2018.
    J Infect Dis. 2021 Apr 27. pii: 6254685. doi: 10.1093.
    PubMed     Abstract available


  8. YUAN W, Huang D, Wu D, Chen Y, et al
    Peg IFN-a Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-gamma in Chronic Hepatitis B.
    J Infect Dis. 2021 Apr 19. pii: 6236316. doi: 10.1093.
    PubMed     Abstract available


  9. LIU Z, Huang CJ, Huang YH, Pan MH, et al
    HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma.
    J Infect Dis. 2021 Apr 14. pii: 6225842. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  10. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  11. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  12. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    PubMed     Abstract available


    December 2020
  13. KIRKEGAARD-KLITBO DM, Bendtsen F, Lundgren J, de Knegt RJ, et al
    Increased prevalence of liver fibrosis in people living with HIV without viral hepatitis compared to population controls.
    J Infect Dis. 2020 Dec 15. pii: 6035145. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  14. LI J, Yang HI, Yeh ML, Le MH, et al
    Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B.
    J Infect Dis. 2020 Nov 29. pii: 6010568. doi: 10.1093.
    PubMed     Abstract available


  15. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  16. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  17. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    PubMed    


  18. THOMAS DL
    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  19. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  20. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  21. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  22. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  23. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  24. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  25. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    PubMed     Abstract available


  26. LIN KY, Fang CT
    Public health responses to person-to-person hepatitis A outbreaks.
    J Infect Dis. 2020 Oct 24. pii: 5937234. doi: 10.1093.
    PubMed    


  27. HOFMEISTER MG, Xing J, Foster MA, Augustine RJ, et al
    Hepatitis A person-to-person outbreaks: Epidemiology, morbidity burden, and factors associated with hospitalization - Multiple States, 2016-2019.
    J Infect Dis. 2020 Oct 24. pii: 5937233. doi: 10.1093.
    PubMed     Abstract available


  28. CHEN S, Zhang Z, Wang Y, Fang M, et al
    Quasispecies pattern of hepatitis B virus predicts hepatocellular carcinoma using deep-sequencing and machine learning.
    J Infect Dis. 2020 Oct 13. pii: 5922597. doi: 10.1093.
    PubMed     Abstract available


  29. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    PubMed    


  30. DEZANET LNC, Maylin S, Gabassi A, Rougier H, et al
    Erratum to: Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
    J Infect Dis. 2020 Oct 7. pii: 5918836. doi: 10.1093.
    PubMed    


    September 2020
  31. RYDELL GE, Larsson SB, Prakash K, Andersson M, et al
    Abundance of non-circular intrahepatic hepatitis B virus DNA may reflect frequent integration into human DNA in chronically infected patients.
    J Infect Dis. 2020 Sep 10. pii: 5903701. doi: 10.1093.
    PubMed     Abstract available


  32. JORDAN AE, Cleland CM, Wyka K, Schackman BR, et al
    Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  33. LEE AB, Karumberia S, Gilmore A, Williams E, et al
    Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  34. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  35. SHERBUK JE, Knick TK, Canan C, Ross P, et al
    Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  36. JORDAN AE, Cleland CM, Schackman BR, Wyka K, et al
    Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  37. ASSOUMOU SA, Paniagua SM, Linas BP, Wang J, et al
    Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  38. WESNER CA, Zhang W, Melstad S, Ruen E, et al
    Assessing County-Level Vulnerability for Opioid Overdose and Rapid Spread of Human Immunodeficiency Virus and Hepatitis C Infection in South Dakota.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  39. WINETSKY D, Burack D, Antoniou P, Garcia B, et al
    Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  40. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


    August 2020
  41. CAPPY P, Lucas Q, Kankarafou N, Sureau C, et al
    No Evidence of HCV-Assisted HDV Propagation in a Large Cohort of Hepatitis C Positive Blood Donors.
    J Infect Dis. 2020 Aug 17. pii: 5893459. doi: 10.1093.
    PubMed     Abstract available


  42. WIJAYA RS, Read SA, Selvamani SP, Schibeci S, et al
    Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells.
    J Infect Dis. 2020 Aug 10. pii: 5890638. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  43. CATLETT B, Bajis S, Starr M, Dore GJ, et al
    Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.
    J Infect Dis. 2020 Jul 25. pii: 5876378. doi: 10.1093.
    PubMed     Abstract available


  44. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study.
    J Infect Dis. 2020 Jul 2. pii: 5866494. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  45. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals.
    J Infect Dis. 2020 Jun 25. pii: 5862583. doi: 10.1093.
    PubMed     Abstract available


  46. MEHROTRA A, D'Angelo JA, Romney-Vanterpool A, Chu T, et al
    IFN-alpha Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation.
    J Infect Dis. 2020;222:148-157.
    PubMed     Abstract available


  47. LE AK, Yang HI, Yeh ML, Jin M, et al
    Development and validation of a risk score for liver cirrhosis prediction in untreated and treated chronic hepatitis B.
    J Infect Dis. 2020 Jun 11. pii: 5856138. doi: 10.1093.
    PubMed     Abstract available


  48. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.
    J Infect Dis. 2020 Jun 9. pii: 5854965. doi: 10.1093.
    PubMed     Abstract available


  49. TAKEUCHI Y, Tsuge M, Tsushima K, Suehiro Y, et al
    Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
    J Infect Dis. 2020 Jun 9. pii: 5854912. doi: 10.1093.
    PubMed     Abstract available


  50. NAGGIE S, Lusk S, Thompson JW, Mock M, et al
    Metabolomic signature as a predictor of liver disease events in patients with HIV/HCV co-infection.
    J Infect Dis. 2020 Jun 5. pii: 5851922. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  51. RONG G, Chen Y, Yu Z, Li Q, et al
    Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
    J Infect Dis. 2020 May 21. pii: 5841650. doi: 10.1093.
    PubMed     Abstract available


  52. ANTHONY DD, Sulkowski MS, Smeaton LM, Damjanovska S, et al
    HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.
    J Infect Dis. 2020 May 15. pii: 5836999. doi: 10.1093.
    PubMed     Abstract available


  53. CHANG WY, Chiu YC, Chiu FW, Hsu YC, et al
    High Risk of clinical relapse in HBV-infected patients after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy.
    J Infect Dis. 2020 May 12. pii: 5836326. doi: 10.1093.
    PubMed     Abstract available


  54. DASGUPTA S, Imamura M, Gorstein E, Nakahara T, et al
    Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
    J Infect Dis. 2020 May 4. pii: 5828592. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  55. SONNEVELD MJ, Hansen BE, Brouwer WP, Chan HL, et al
    hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study.
    J Infect Dis. 2020 Apr 21. pii: 5823493. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  56. FAN R, Peng J, Xie Q, Tan D, et al
    Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients.
    J Infect Dis. 2020 Mar 25. pii: 5811444. doi: 10.1093.
    PubMed     Abstract available


  57. BALAGOPAL A, Smeaton LM, Quinn J, Venuto CS, et al
    Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.
    J Infect Dis. 2020 Mar 23. pii: 5810960. doi: 10.1093.
    PubMed     Abstract available


  58. SUN B, Abadjian L, Monto A, Freasier H, et al
    HCV cure in HIV coinfection dampens inflammation and improves cognition through multiple mechanisms.
    J Infect Dis. 2020 Mar 11. pii: 5802775. doi: 10.1093.
    PubMed     Abstract available


  59. AKIYAMA MJ, Lipsey D, Ganova-Raeva L, Punkova L, et al
    A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    J Infect Dis. 2020 Mar 9. pii: 5801905. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  60. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C.
    J Infect Dis. 2020 Feb 15. pii: 5736576. doi: 10.1093.
    PubMed    


    January 2020
  61. LINAS BP
    Time for a New Approach to Guidance for HIV and HCV Testing Among Persons Who Inject Drugs.
    J Infect Dis. 2020 Jan 30. pii: 5718241. doi: 10.1093.
    PubMed    


  62. BULL-OTTERSON L, Huang YA, Zhu W, King H, et al
    HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017.
    J Infect Dis. 2020 Jan 30. pii: 5718242. doi: 10.1093.
    PubMed     Abstract available


  63. MARAVELIA P, Frelin L, Ni Y, Perez NC, et al
    Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections.
    J Infect Dis. 2020 Jan 29. pii: 5717223. doi: 10.1093.
    PubMed     Abstract available


  64. GREBELY J, Catlett B, Jayasinghe I, Valerio H, et al
    Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis.
    J Infect Dis. 2020 Jan 29. pii: 5717213. doi: 10.1093.
    PubMed     Abstract available


  65. DEZANET LNC, Maylin S, Gabassi A, Rougier H, et al
    Kinetics of hepatitis B core-related antigen and anti-hepatitis B core antibody and their association with serological response in HIV-hepatitis B co-infection.
    J Infect Dis. 2020 Jan 21. pii: 5710864. doi: 10.1093.
    PubMed     Abstract available


  66. SAKAMOTO K, Umemura T, Ito K, Okumura A, et al
    Virological Factors Associated With the Occurrence of Hepatitis B Virus (HBV) Reactivation in Patients With Resolved HBV Infection Analyzed Through Ultradeep Sequencing.
    J Infect Dis. 2020;221:400-407.
    PubMed     Abstract available


  67. CLIPMAN SJ, Duggal P, Srikrishnan AK, Saravanan S, et al
    Prevalence and phylogenetic characterization of hepatitis C among men who have sex with men in India: limited evidence for sexual transmission.
    J Infect Dis. 2020 Jan 9. pii: 5699640. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  68. LOFFREDO-VERDE E, Bhattacharjee S, Malo A, Festag J, et al
    Dynamic, Helminth-Induced Immune Modulation Influences the Outcome of Acute and Chronic Hepatitis B Virus Infection.
    J Infect Dis. 2019 Dec 25. pii: 5686810. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  69. YURDAYDIN C, Toy M
    Hepatitis Delta Virus Infection: A Large Burden After All?
    J Infect Dis. 2019 Nov 28. pii: 5645272. doi: 10.1093.
    PubMed    


  70. MIAO Z, Zhang S, Ou X, Li S, et al
    Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection.
    J Infect Dis. 2019 Nov 28. pii: 5645271. doi: 10.1093.
    PubMed     Abstract available


  71. BALAGOPAL A, Hwang HS, Grudda T, Quinn J, et al
    Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Co-infection.
    J Infect Dis. 2019 Nov 19. pii: 5628941. doi: 10.1093.
    PubMed     Abstract available


  72. KOVACS AAZ, Kono N, Wang CH, Wang D, et al
    Association of HLA Genotype With T-Cell Activation in Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus-Coinfected Women.
    J Infect Dis. 2019 Nov 10. pii: 5618844. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  73. COLSON P, Borentain P, Ravaux I, Aherfi S, et al
    Hepatitis B virus genomics knocks at the door of routine diagnosis laboratories.
    J Infect Dis. 2019 Oct 19. pii: 5599737. doi: 10.1093.
    PubMed    


  74. CHIHOTA BV, Wandeler G, Chilengi R, Mulenga L, et al
    High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
    J Infect Dis. 2019 Oct 15. pii: 5581876. doi: 10.1093.
    PubMed     Abstract available


  75. SU TH, Peng CY, Tseng TC, Yang HC, et al
    Serum Mac-2-binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B related cirrhosis.
    J Infect Dis. 2019 Oct 1. pii: 5580041. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  76. ZOU B, Yeo YH, Le MH, Henry L, et al
    Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.
    J Infect Dis. 2019 Sep 27. pii: 5575100. doi: 10.1093.
    PubMed     Abstract available


  77. YANG HI, Yeh ML, Wong GL, Peng CY, et al
    REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy.
    J Infect Dis. 2019 Sep 24. pii: 5573337. doi: 10.1093.
    PubMed     Abstract available


  78. YE J, Wu Y, Li M, Gong X, et al
    Keratin 8 mutations were associated with susceptibility to chronic hepatitis B and related progression.
    J Infect Dis. 2019 Sep 13. pii: 5568471. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  79. TRESSLER SR, Kushner T, Bhandari R
    Factors Associated with Hepatitis B Exposure among People who Report Using Methamphetamine: NHANES 2009-2016.
    J Infect Dis. 2019 Aug 30. pii: 5556601. doi: 10.1093.
    PubMed     Abstract available


  80. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    PubMed     Abstract available


  81. EMMANUEL B, El-Kamary SS, Magder LS, Stafford KA, et al
    Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-DeltaG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.
    J Infect Dis. 2019 Aug 26. pii: 5554606. doi: 10.1093.
    PubMed     Abstract available


  82. SALPINI R, Pietrobattista A, Piermatteo L, Basso MS, et al
    Establishment of a seronegative occult infection with an active HBV reservoir enriched of vaccine escape mutations in a vaccinated infant after liver transplant.
    J Infect Dis. 2019 Aug 14. pii: 5550108. doi: 10.1093.
    PubMed     Abstract available


  83. CHOI YH, Perez-Cuevas MB, Kodani M, Zhang X, et al
    Feasibility of Hepatitis B Vaccination by Microneedle Patch: Cellular and Humoral Immunity Studies in Rhesus Macaques.
    J Infect Dis. 2019 Aug 13. pii: 5549399. doi: 10.1093.
    PubMed     Abstract available


  84. WANG K, Lin W, Kuang Z, Fan R, et al
    Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients.
    J Infect Dis. 2019 Aug 2. pii: 5542793. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  85. MARTIN NK, Jansen K, An der Heiden M, Boesecke C, et al
    Can HCV be eliminated among HIV-positive men who have sex with men in Berlin? A modeling analysis.
    J Infect Dis. 2019 Jul 12. pii: 5532024. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  86. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C.
    J Infect Dis. 2019 Jun 4. pii: 5511345. doi: 10.1093.
    PubMed     Abstract available


  87. HAN JW, Sung PS, Kim KH, Hong SH, et al
    Dynamic Changes in Ex Vivo T-Cell Function after Viral Clearance in Chronic HCV Infection.
    J Infect Dis. 2019 Jun 1. pii: 5510067. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  88. YAN Y, Wang X, Lou P, Hu Z, et al
    A nanoparticle-based HCV vaccine with enhanced potency.
    J Infect Dis. 2019 May 10. pii: 5487910. doi: 10.1093.
    PubMed     Abstract available


  89. LAIDLAW SM, Dustin LB
    An HCV vaccine on the fly.
    J Infect Dis. 2019 May 10. pii: 5487908. doi: 10.1093.
    PubMed    


  90. SAYED IM
    Hepatic immune response against Hepatitis E virus genotype 1 infection among animal models.
    J Infect Dis. 2019 May 7. pii: 5486414. doi: 10.1093.
    PubMed    


  91. LIU F, Seto WK, Wong DK, Huang FY, et al
    Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B.
    J Infect Dis. 2019 May 6. pii: 5485908. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  92. OESER C, Vaughan A, Said B, Ijaz S, et al
    Epidemiology of Hepatitis E in England and Wales: A 10-Year Retrospective Surveillance Study, 2008-2017.
    J Infect Dis. 2019 Apr 24. pii: 5479512. doi: 10.1093.
    PubMed     Abstract available


  93. SAYED IM, Verhoye L, Montpellier C, Abravanel F, et al
    Study of hepatitis E virus ORF2 antigen kinetics in human-liver chimeric mice and its impact on HEV diagnosis.
    J Infect Dis. 2019 Apr 18. pii: 5475180. doi: 10.1093.
    PubMed     Abstract available


  94. DOUGLAS MW, Tay ES, Eden JS, George J, et al
    Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir.
    J Infect Dis. 2019 Apr 8. pii: 5431216. doi: 10.1093.
    PubMed    


  95. HUANG CF, Hung CH, Cheng PN, Bair MJ, et al
    An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated subst
    J Infect Dis. 2019 Apr 8. pii: 5430846. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  96. BOCKMANN JH, Stadler D, Xia Y, Ko C, et al
    Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus infected hepatocytes.
    J Infect Dis. 2019 Mar 29. pii: 5421826. doi: 10.1093.
    PubMed     Abstract available


  97. ABARA WE, Trujillo L, Broz D, Finlayson T, et al
    Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015.
    J Infect Dis. 2019 Mar 27. pii: 5420467. doi: 10.1093.
    PubMed     Abstract available


  98. ZHANG Z, Liang Z, Zeng J, Zhang J, et al
    Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with recombinant hepatitis B vaccine and group A meningococcal polysaccharide vaccine: a phase IV, open-label, single-center, randomized, non-inferiority tr
    J Infect Dis. 2019 Mar 19. pii: 5395971. doi: 10.1093.
    PubMed     Abstract available


  99. KUSEJKO K, Bachmann N, Chaudron SE, Nguyen H, et al
    A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.
    J Infect Dis. 2019 Mar 4. pii: 5369724. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  100. SALAZAR-VIZCAYA L, Kouyos RD, Metzner KJ, Caraballo Cortes K, et al
    Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era.
    J Infect Dis. 2019 Feb 13. pii: 5318573. doi: 10.1093.
    PubMed     Abstract available


  101. LEUNG J, Peacock A, Colledge S, Grebely J, et al
    A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
    J Infect Dis. 2019 Feb 6. pii: 5307802. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  102. LIU KSH, Seto WK, Lau EHY, Wong DK, et al
    A territory-wide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong.
    J Infect Dis. 2019 Jan 18. pii: 5298202. doi: 10.1093.
    PubMed     Abstract available


  103. CHEN CH, Hung CH, Wang JH, Lu SN, et al
    The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy.
    J Infect Dis. 2019 Jan 17. pii: 5299647. doi: 10.1093.
    PubMed     Abstract available


  104. ANDONOV A, Robbins M, Borlang J, Cao J, et al
    Rat hepatitis E virus linked to severe acute hepatitis in an immunocompetent patient.
    J Infect Dis. 2019 Jan 11. pii: 5288497. doi: 10.1093.
    PubMed     Abstract available


  105. RAGHWANI J, Wu CH, Ho CKY, De Jong M, et al
    High resolution evolutionary analysis of within-host hepatitis C virus infection.
    J Infect Dis. 2019 Jan 2. pii: 5269822. doi: 10.1093.
    PubMed     Abstract available


  106. KAPLAN D
    Causal Inference for Observational Studies.
    J Infect Dis. 2019;219:1-2.
    PubMed    


    December 2018
  107. NASTASIO S, Jonas MM
    Editorial: The Impact of Universal Infant Hepatitis B Virus Immunization on reducing the Hepatitis B Carrier Rate in Pregnant Women.
    J Infect Dis. 2018 Dec 20. pii: 5253870. doi: 10.1093.
    PubMed    


  108. SU WJ, Chen SF, Yang CH, Chuang PH, et al
    The Impact of Universal Infant Hepatitis B Immunization on reducing the Hepatitis B Carrier Rate in Pregnant Women.
    J Infect Dis. 2018 Dec 20. pii: 5253892. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  109. PIROZYAN MR, Nguyen N, Cameron B, Luciani F, et al
    Chemokine-regulated recruitment of antigen-specific T cell sub-populations to the liver in acute and chronic hepatitis C infection.
    J Infect Dis. 2018 Nov 29. pii: 5213654. doi: 10.1093.
    PubMed     Abstract available


  110. PRICE JC, McKinney JE, Crouch PC, Dillon SM, et al
    Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV.
    J Infect Dis. 2018 Nov 20. pii: 5193510. doi: 10.1093.
    PubMed     Abstract available


  111. YEH ML, Huang CI, Huang CF, Hsieh MH, et al
    Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients.
    J Infect Dis. 2018 Nov 19. pii: 5191105. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  112. LAROUCHE A, Milton McSween KA, Calderon V, Fauteux-Daniel S, et al
    Quasispecies Diversity Is a Major Risk Factor for Vertical Hepatitis C Virus Transmission.
    J Infect Dis. 2018 Oct 25. pii: 5144832. doi: 10.1093.
    PubMed     Abstract available


  113. THAN TT, Jo E, Todt D, Nguyen PH, et al
    High environmental stability of hepatitis B virus and inactivation requirements for chemical biocides.
    J Infect Dis. 2018 Oct 24. pii: 5144374. doi: 10.1093.
    PubMed     Abstract available


  114. CHOI Y, Zhang X, Skinner B
    Analysis of IgG anti-HEV antibody protective levels during hepatitis E virus reinfection in experimentally infected rhesus macaques.
    J Infect Dis. 2018 Oct 16. pii: 5132976. doi: 10.1093.
    PubMed     Abstract available


  115. TURPIN J, Yurick D, Khoury G, Pham H, et al
    Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia.
    J Infect Dis. 2018 Oct 11. pii: 5126831. doi: 10.1093.
    PubMed     Abstract available


    September 2018
  116. TANG L, Chen C, Gao X, Zhang W, et al
    Interleukin-21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection.
    J Infect Dis. 2018 Sep 27. pii: 5107682. doi: 10.1093.
    PubMed     Abstract available


  117. LANDAHL J, Bockmann JH, Scheurich C, Ackermann C, et al
    Detection of a broad range of low level MHC class II-restricted Hepatitis Delta Virus (HDV)-specific T cell responses regardless of the clinical status.
    J Infect Dis. 2018 Sep 23. pii: 5106138. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  118. ANKCORN M, Moreira F, Ijaz S, Symes A, et al
    Absence of persistent Hepatitis E virus infection in antibody-deficient patients is associated with the transfer of antigen neutralising antibodies from immunoglobulin products.
    J Infect Dis. 2018 Aug 18. pii: 5075995. doi: 10.1093.
    PubMed     Abstract available


  119. THOENS C, Heinold A, Lindemann M, Horn PA, et al
    A single nucleotide polymorphism upstream of the HLA-C locus is associated with an anti-HCV seronegative state in a high-risk exposed cohort.
    J Infect Dis. 2018 Aug 9. pii: 5068404. doi: 10.1093.
    PubMed     Abstract available


  120. VELAZQUEZ-MOCTEZUMA R, Galli A, Law M, Bukh J, et al
    Hepatitis C virus escape studies for human monoclonal antibody AR4A reveal isolate-specific resistance and a high barrier to resistance.
    J Infect Dis. 2018 Aug 9. pii: 5068268. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  121. LOPEZ-CORTES LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, et al
    Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    J Infect Dis. 2018 Jul 6. pii: 5050122. doi: 10.1093.
    PubMed     Abstract available


  122. NGUYEN MH, Yang HI, Le A, Henry L, et al
    Reduced Incidence of Hepatocellular Carcinoma with Tenofovir in Chronic Hepatitis B Patients with and without Cirrhosis - a Propensity Score Matched Study.
    J Infect Dis. 2018 Jul 5. pii: 5049301. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  123. BORGIA SM, Hedskog C, Parhy B, Hyland RH, et al
    Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes.
    J Infect Dis. 2018 Jun 30. pii: 5047409. doi: 10.1093.
    PubMed     Abstract available


  124. HELFRITZ FA, Bojkova D, Wanders V, Kuklinski N, et al
    Methylene Blue Treatment of Grafts during Cold Ischemia time Reduces the Risk of HCV Transmission.
    J Infect Dis. 2018 Jun 23. pii: 5043304. doi: 10.1093.
    PubMed     Abstract available


  125. HONER ZU SIEDERDISSEN C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, et al
    Contrasting Timing of Virological Relapse after Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-negative Patients.
    J Infect Dis. 2018 Jun 9. pii: 5035294. doi: 10.1093.
    PubMed     Abstract available


  126. LIDOFSKY A, Holmes JA, Feeney ER, Kruger AJ, et al
    Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection.
    J Infect Dis. 2018 Jun 4. pii: 5032604. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  127. MAHALE P, Aka PV, Chen X, Liu P, et al
    Hepatitis D Viremia Among Injection Drug Users in San Francisco.
    J Infect Dis. 2018;217:1902-1906.
    PubMed     Abstract available


  128. VAN BOMMEL F, van Bommel A, Krauel A, Wat C, et al
    Serum HBV RNA as a Predictor of Peginterferon Alfa-2a (40KD) Response in Patients With HBeAg-Positive Chronic Hepatitis B.
    J Infect Dis. 2018 May 8. pii: 4993824. doi: 10.1093.
    PubMed     Abstract available


  129. LEE IC, Yang SS, Lee CJ, Su CW, et al
    Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study.
    J Infect Dis. 2018 May 7. pii: 4993347. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  130. MAY S, Mandal S, Keel P, Haywood B, et al
    Hepatitis B virus immunisation and neonatal acquisition of persistent infection in England and Wales.
    J Infect Dis. 2018 Apr 24. pii: 4982944. doi: 10.1093.
    PubMed     Abstract available


  131. LIN KY, Hsieh SM, Sheng WH, Lo YC, et al
    Comparable serologic responses to 2 different combinations of inactivated HAV vaccines in HIV-positive patients during the acute hepatitis A outbreak in Taiwan.
    J Infect Dis. 2018 Apr 16. pii: 4972613. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  132. FRITZ M, Berger B, Schemmerer M, Endres D, et al
    Pathological Cerebrospinal Fluid Findings in Patients with Neuralgic Amyotrophy and Acute Hepatitis E Virus Infection.
    J Infect Dis. 2018 Mar 14. pii: 4935502. doi: 10.1093.
    PubMed     Abstract available


  133. RAGONNET-CRONIN M, Jackson C, Bradley-Stewart A, Aitken C, et al
    Recent and Rapid Transmission of HIV among People who Inject Drugs in Scotland Revealed through Phylogenetic Analysis.
    J Infect Dis. 2018 Mar 13. pii: 4931169. doi: 10.1093.
    PubMed     Abstract available


  134. COOPER CL
    Now is the Time to Quickly Eliminate Barriers along the Hepatitis C Cascade of Care.
    J Infect Dis. 2018 Mar 9. pii: 4925219. doi: 10.1093.
    PubMed    


  135. LAMOURY FMJ, Bajis S, Hajarizadeh B, Marshall AD, et al
    Evaluation of the Xpert(R) HCV Viral Load Fingerstick point-of-care assay.
    J Infect Dis. 2018 Mar 9. pii: 4925218. doi: 10.1093.
    PubMed     Abstract available


  136. PEIFFER KH, Kuhnhenn L, Jiang B, Mondorf A, et al
    Divergent preS sequences in virion associated hepatitis B virus genomes and subviral HBV surface antigen particles from HBV e antigen negative patients.
    J Infect Dis. 2018 Mar 8. pii: 4924691. doi: 10.1093.
    PubMed     Abstract available


  137. STROUVELLE VP, Braun DL, Vongrad V, Scherrer AU, et al
    No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients.
    J Infect Dis. 2018 Mar 8. pii: 4924783. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  138. ZIMMER CL, Rinker F, Honer Zu Siederdissen C, Manns MP, et al
    Increased NK Cell Function after Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Associates with Liver Damage and HBsAg Loss.
    J Infect Dis. 2018 Feb 17. pii: 4868650. doi: 10.1093.
    PubMed     Abstract available


  139. DOU Y, van Montfoort N, van den Bosch A, de Man RA, et al
    HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.
    J Infect Dis. 2018;217:827-839.
    PubMed     Abstract available


  140. SORIANO V, Aguilera A
    Hepatitis Delta Enters a New Therapeutic Era.
    J Infect Dis. 2018 Feb 7. pii: 4841648. doi: 10.1093.
    PubMed    


  141. YURDAYDIN C, Keskin O, Kalkan C, Karakaya F, et al
    Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.
    J Infect Dis. 2018 Feb 7. pii: 4841647. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  142. WU JF, Song SH, Lee CS, Chen HL, et al
    Clinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults.
    J Infect Dis. 2018 Jan 30. pii: 4829563. doi: 10.1093.
    PubMed     Abstract available



  143. Erratum: Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2018 Jan 27. pii: 4827080. doi: 10.1093.
    PubMed    


  144. ROLT A, Le D, Hu Z, Wang AQ, et al
    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093.
    PubMed     Abstract available


  145. SANAKA S, Kasarala GR, Tillmann HL
    A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression.
    J Infect Dis. 2018 Jan 21. pii: 4770294. doi: 10.1093.
    PubMed     Abstract available


  146. WILSON P, Parr JB, Jhaveri R, Meshnick SR, et al
    Call to action: Prevention of mother-to-child transmission of hepatitis B in Africa.
    J Infect Dis. 2018 Jan 17. pii: 4812591. doi: 10.1093.
    PubMed     Abstract available


  147. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    PubMed     Abstract available


  148. LIU H, Li F, Zhang X, Yu J, et al
    Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase.
    J Infect Dis. 2018 Jan 2. pii: 4782485. doi: 10.1093.
    PubMed     Abstract available


  149. SU TH, Yang HC, Tseng TC, Liou JM, et al
    Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy.
    J Infect Dis. 2018 Jan 2. pii: 4782512. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  150. PERUMALSWAMI PV, Talal AH
    Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders.
    J Infect Dis. 2017 Dec 26. pii: 4774700. doi: 10.1093.
    PubMed    


  151. STEPANOVA M, Thompson A, Doyle J, Younossi I, et al
    Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
    J Infect Dis. 2017 Dec 26. pii: 4774699. doi: 10.1093.
    PubMed     Abstract available


  152. BOPPANA SB, Britt WJ, Fowler K, Hutto SC, et al
    Pathogenesis of Non-Zika Congenital Viral Infections.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


    November 2017
  153. BOON D, Redd AD, Layendecker O, Engle R, et al
    Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda.
    J Infect Dis. 2017 Nov 23. pii: 4653785. doi: 10.1093.
    PubMed     Abstract available


  154. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Abstract available


  155. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Abstract available


  156. YANG HC, Shih YF, Liu CJ
    Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  157. SU TH, Kao JH
    Unmet Needs in Clinical and Basic Hepatitis B Virus Research.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  158. TSENG TC, Huang LR
    Immunopathogenesis of Hepatitis B Virus.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  159. WU D, Ning Q
    Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  160. LIU CJ, Kao JH
    NOhep: Toward Global Control of Hepatitis B Virus Infection-An Introduction.
    J Infect Dis. 2017;216.
    PubMed    


  161. CHOI J, Lim YS
    Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  162. BUTI M, Riveiro-Barciela M, Esteban R
    Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  163. CHEN HL, Wen WH, Chang MH
    Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission.
    J Infect Dis. 2017;216.
    PubMed     Abstract available


  164. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  165. TALAL AH, Dumas EO, Bauer B, Rejman RM, et al
    Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    J Infect Dis. 2017 Sep 27. pii: 4210613. doi: 10.1093.
    PubMed     Abstract available


  166. CHANG Y, Choe WH, Sinn DH, Lee JH, et al
    Nucleos(t)ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Abstract available


  167. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Abstract available


    August 2017
  168. BOEIJEN LL, Montanari NR, de Groen RA, van Oord GW, et al
    Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    PubMed     Abstract available


  169. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Abstract available


  170. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Abstract available


    April 2017
  171. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Abstract available


    March 2017
  172. VAN DER REE MH, Jansen L, Kruize Z, van Nuenen AC, et al
    Plasma microRNA levels are associated with HBeAg status and treatment response in chronic hepatitis B patients.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Abstract available


  173. CHI H, Hansen BE, Guo S, Zhang NP, et al
    Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    J Infect Dis. 2017 Mar 17. doi: 10.1093.
    PubMed     Abstract available


  174. CHEN GJ, Lin KY, Hung CC, Chang SC, et al
    Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed    


  175. WANG L, Wen J, Gao F, Hao H, et al
    Hepatitis E virus-associated neurological injury in China.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed    


  176. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  177. HAN Y, Gu L, Liu J, Li X, et al
    Association of mutations in TLR2 signaling genes with fulminant form of hepatitis B related acute liver failure.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Abstract available


    January 2017
  178. CAO J, Chi H, Yu T, Li Z, et al
    Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    J Infect Dis. 2017 Jan 19. doi: 10.1093.
    PubMed     Abstract available


    September 2016
  179. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Abstract available


    July 2016
  180. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: